Prosecution Insights
Last updated: November 04, 2026
Application No. 18/142,513

METHODS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Non-Final OA §103§DP
Filed
May 02, 2023
Priority
Nov 04, 2020 — provisional 63/109,811 +4 more
Examiner
BELYAVSKYI, MICHAIL A
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Orca Biosystems Inc.
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
718 granted / 1122 resolved
+4.0% vs TC avg
Strong +28% interview lift
Without
With
+28.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
44 currently pending
Career history
1204
Total Applications
across all art units

Statute-Specific Performance

§101
3.6%
-36.4% vs TC avg
§103
31.3%
-8.7% vs TC avg
§102
14.9%
-25.1% vs TC avg
§112
19.7%
-20.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1122 resolved cases

Office Action

§103 §DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION 1 Claims 215-234 are pending. 2. Applicant’s election without traverse of Group I, claims 215-230 in the reply filed on 06/16/26 is acknowledged. 3. Claims 231-234 withdrawn from further consideration by the Examiner, 37 C.F.R. § 1.142(b) as being drawn to nonelected inventions. Claims 215-230 read on a multi-component composition are under consideration in the instant application. 4. It is noted that during patent examination, the pending claims must be "given the broadest reasonable interpretation consistent with the specification." See MPEP 2100. Thus, when claim215 is given its broadest reasonable interpretation , it can read on multi-component pharmaceutical composition for treatment. 5. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 6. Claims 215-230 are rejected under 35 U.S.C. 103 as being unpatentable over US Patent Application US Patent Application 20210030797 and US Patent Application 20250019656 US Patent Application ‘797 teaches a multi-component pharmaceutical composition for hematopoietic stem cells transplantation comprising HSPC, Treg and tacrolimus. US Patent Application ‘797 teaches that said HSPC can comprise granulocytes ( see entire document, paragraphs 0005, 0025, 0031, 0036 in particular). US Patent Application ‘656 teaches a multi-component pharmaceutical composition for hematopoietic stem cells transplantation comprising HSPC and regulatory CD45+ cells comprising CD3+ T cells ( see entire document paragraph 0036 and 0046 in particular). All the claimed elements were known in the prior art and one skill in the art could have combine the elements as claimed by known methods with no change in their respective function and the combination would have yield predictable results to one of ordinary skill in the art at the time of the invention ( see KSR International Co v Teleflex Inc., 550U.S.-, 82 USPQ2d 1385, 2007). Thus it would have been to one of ordinary skill in the art before the effective filing date of the claimed invention to use a second population of CD45+ cells comprising CD3 cells in multi-component pharmaceutical composition taught by US Patent Application 656 for hematopoietic stem cells transplantation taught by US Patent Application 797 with a reasonable expectation of success because the prior art suggests both multi-component composition can be used for hematopoietic stem cells transplantation. “It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose. . . [T]he idea of combining them flows logically from their having been individually taught in the prior art.” In re Kerkhoven, 626 F.2d 846, 850, 205USPQ 1069, 1072 (CCPA 1980) (see MPEP 2144.06). Claims 224-230 are included because the instant claims are drawn to a composition not a method of treating . Thus, it is the Examiner’s position that the intended use of the claimed composition only limits the claim to the extent that the prior art must be capable of performing the purpose or intended use. From the combined teaching of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. 7. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 8. The claim 215-230 are provisionally rejected on the grounds of nonstatutory double patenting of the claims of copending Application No. 19/558,231 and 18/916,371 Although the conflicting claims are not identical, they are not patentably distinct from each other because claims of copending Application No. 19/558,231 and 18/916,371 each recited a multi-component pharmaceutical composition comprising first population comprising HSPCs, Treg tacrolimus and a second population comprising CD45+ T cells. This is a provisional nonstatutory double patenting rejection because the conflicting claims have not in fact been patented. 9. No claim is allowed. 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michail Belyavskyi whose telephone number is 571/272-0840. The examiner can normally be reached Monday through Friday from 9:00 AM to 5:30 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gregory Emch can be reached on 571/ 272-8149 The fax number for the organization where this application or proceeding is assigned is 571/273-8300 Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /MICHAIL A BELYAVSKYI/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

May 02, 2023
Application Filed
Aug 05, 2026
Non-Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780888
NOVEL IMMUNOMODULATOR
4y 1m to grant Granted Nov 03, 2026
Patent 12780887
MUTATION COMPLEX INCLUDING GAIN-OF-FUNCTION MUTANT OF BMPR2 GENE, INDUCED PLURIPOTENT STEM CELLS AND MESENCHYMAL STEM CELLS DERIVED FROM MUTANT, AND USE THEREOF
3y 10m to grant Granted Nov 03, 2026
Patent 12766186
NERVE GROWTH FACTOR MUTANT
3y 8m to grant Granted Oct 20, 2026
Patent 12767715
SINGLE-DOMAIN ANTIBODY TARGETING PD-1, DERIVATIVE THEREOF AND USE THEREOF
3y 3m to grant Granted Oct 20, 2026
Patent 12760091
FIBRONECTIN TARGETING CHIMERIC ANTIGEN RECEPTORS (CARS)
4y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
92%
With Interview (+28.0%)
3y 1m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1122 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month